Showing 1199 results
- Media Release /Wachstum des Nettoumsatzes im Jahr 2014 - mit starker Erhöhung der Kerngewinnmarge[1] Der Nettoumsatz steigt 2014 um 1% (+3% kWk[1])[2] auf USD 58,0 Milliarden (4. Quartal: -2%, +4% kWk) Das…
- Media Release /With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a flexible…
- Media Release /Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (…
- Media Release /Offering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A[1],[2] Phase III data demonstrated…
- Media Release /Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other…
- Media Release /Novartis establishing a joint investment company with Qualcomm Ventures, the venture investment group of Qualcomm Incorporated, of up to USD 100 million to support early stage companies with…
- Media Release /Pivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung function in COPD patients[1-5] US trials for QVA149 demonstrated significant…
- Media Release /Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested…
- Media Release /Collaborations give Novartis access to novel CRISPR technology platforms for the discovery and development of new medicines Intellia Therapeutics collaboration to explore therapeutic options for…
Pagination
- ‹ Previous page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- › Next page